| Category : |
Intermediates |
 |
| CAS NO : |
191732-72-6 |
| EC NO : |
|
| MF : |
C13H13N3O3 |
| MW : |
259.2606 |
| Specification : |
98% up, Medicine Grade |
| Packing : |
25kg/drum |
| Product description : |
Function of Lenalidomide
1. Lenalidomide API is an anti-tumor drug developed by Celgene biopharmaceutical company. The chemical structure is similar to thalidomide, which has multiple functions such as anti-tumor, immune regulation and anti-angiogenesis.
2. Lenalidomide inhibits the secretion of proinflammatory cytokines and increases the secretion of anti-inflammatory cytokines in peripheral blood monocytes.
3. Lenalidomide can also inhibit the expression of cyclooxygenase 2(cox-2), but it has no effect on cox-1.
4. Lenalidomide besides can be used to treat MDS and MM, for multiple myeloma, leukemia, metastatic renal cell carcinoma, solid tumor, idiopathic generalized the degeneration amylum and with marrow unripe systemic bone marrow fibrosis disease have certain curative effect.
5. Lenalidomide is currently the most effective drug to treat multiple myeloma. |
| Uses : |
Lenalidomide is currently the most effective drug to treat multiple myeloma. |
| Synonyms : |
3-(7-amino-3-oxo-1h-isoindol-2-yl)piperidine-2,6-dione;1-Oxo-2-(2,6-dioxopiperidin-3-yl)-4-aminoisoindoline;3-(4-Amino-1,3-dihydro-1-oxo-2H-isoindol-2-yl)-2,6-piperidinedione;CC-5013;Revlimi;Lenalidomide(other anti-cancers);3-(4-amino-1-oxo-1,3-dihydro-2H-isoindol-2-yl)piperidine-2,6-dione; |
| Molecular Structure : |
 |